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Abstract: The diverse abilities of cerium oxide nanoparticles (CONPs) have encouraged researchers to pursue 
CONPs as a therapeutic agent to treat a number of diseases, including cancer. In vitro and in vivo studies have 
shown CONPs to be toxic to cancer cells, inhibit invasion, and sensitize cancer cells to radiation therapy. However, 
CONPs display minimal toxicity to normal tissues and provide protection from various forms of reactive oxygen spe-
cies (ROS) generation. The antioxidant capabilities of CONPs, which enable radiation protection, have also resulted 
in the exploration of these particles as a potential treatment for other disorders characterized by ROS accumula-
tion, such as diabetes and macular degeneration. While critical information regarding the uptake, retention, and 
clearance of these particles is incomplete and conflicting reports exist about in vitro toxicity, most research into the 
various applications of CONPs has yielded promising data. This review highlights the current research into cerium 
oxide nanoparticles as a novel therapeutic for the treatment of cancer and other diseases.
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Introduction
In recent years, nanotechnology has become a 
main focus of biomedical research. Nanoparti- 
cles applications include drug delivery systems, 
luminescent biomarkers, and tissue engineer-
ing, among others [1]. In particular, cerium 
oxide nanoparticles (CONPs), which consist of a 
cerium core surrounded by an oxygen lattice, 
have shown promise in a number of applica-
tions. Originally of interest for the ability of sur-
face oxygen vacancies to interact with and 
modulate free radicals, CONPs have since been 
shown to display a number of antioxidant 
behaviors, including superoxide dismutase 
(SOD) activity [2], catalase mimetic activity [3], 
nitric oxide radical scavenging [4], and hydroxyl 
radical scavenging [5]. However, tissue or cell 
environmental conditions appear to play an 
important role in the determination of activity, 
as CONPs also possess direct oxidant behavior 
[6]. To date, pH is one of the few factors shown 
to drive whether CONPs act as oxidants or anti-
oxidants [7, 8].
As cellular levels of reactive oxygen species 
(ROS) are tightly controlled in normal, healthy 
cells [9], the ability to modulate the redox sta-
tus of cells has applications in diseases where 
ROS levels have become de-regulated or are 
altered by treatment. Though more recently 
linked to cell proliferation and survival, ROS 
accumulation is generally associated with 
undesired effects, having been linked to neuro-
degenerative diseases, diabetes, atherosclero-
sis, and even aging [9]. In cancer, which causes 
over 500,000 deaths per year [10], ROS can 
drive both the initial development and progres-
sion, as well as down regulate antioxidant 
enzymes that normally combat radical produc-
tion [11]. Studies have shown CONPs to pos-
sess innate cytotoxicity to cancer cells, anti-
invasive properties, and the ability to sensitize 
cancer cells to radiation induced cell death, 
while protecting the surrounding normal tissues 
(Figure 1). Additionally, CONP treatment has 
been shown to prevent macular degeneration 
[12] and the formation of neovascular lesions in 
the retina [13], as well as decrease hepatic ROS 
levels linked to the progression of diabetes 
[14]. Thus, CONPs have extensive potential as a 
therapeutic agent for the treatment of cancer, 
as well as other diseases in which ROS have 
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been implicated. Potential applications of 
CONPs are summarized in Figure 1 with brief 
description of ROS-dependent mechanisms 
that are discussed in further details below.
CONP effect on cancer
Anti-invasive properties
In addition to CONPs’ toxicity to cancer cells in 
vitro and in vivo, studies have shown polymer-
coated CONPs to also manipulate tumor-stro-
mal interactions to the detriment of tumor pro-
gression and invasion [15]. Polymer coating of 
CONPs increases aqueous solubility [7], yet 
does not appear to impact CONP redox activi-
ties [6, 15]. Epithelial/stromal signaling is 
largely mediated by myofibroblasts, which play 
a key role in the expression of extracellular 
matrix components, including α-smooth mus-
cle actin and collagen, to facilitate tumor inva-
sion and angiogenesis [16]. With the transition 
from fibroblast to myofirbroblast driven by 
transforming growth factor beta 1 (TGFβ1) 
-induced ROS-dependent expression of 
α-smooth muscle actin, data shows CONPs 
possess the ability to modulate myofibroblast 
formation [15]. Pre-treatment with CONPs miti-
gated both TGFβ1-induced α-smooth muscle 
actin expression in fibroblasts and the corre-
sponding myofibroblast transition [15]. As some 
myofibroblasts localize to the invasion front of 
tumors, CONP treatment diminished the ability 
of myofibroblasts to induce invasion by squa-
mous tumor cells in vitro [15]. Interestingly, 
CONPs were also able to decrease the intrinsic 
ability of cultured squamous tumor cells to 
invade, even in the absence of any myofibro-
blast stimulation [15]. Taken together, these 
data demonstrate the direct negative effects of 
CONPs on cancer cells, as well as their ability to 
modulate the tumor environment and indirectly 
inhibit tumor cell invasion.
Radio-protection and radio-sensitization
The ability of CONPs to modulate ROS has led 
to their exploration for the improvement of a 
current cancer treatment: radiation therapy 
(RT). In addition to surgery and chemotherapy, 
RT remains a mainstay in the treatment of can-
cer, with nearly half of all cancer patients 
receiving RT at some point during treatment 
[17]. Many harmful side effects are associated 
with the RT, including fatigue, nausea, and der-
matitis, yet few radiation adjuvants are avail-
able to mitigate these painful outcomes. For 
example, Amifostine, which remains the only 
clinically available radio-protectant [17], is itself 
associated with nausea and hypotension [18]. 
Figure 1. Potential therapeutic applications of CONPs. The various diseases in which CONPs have been tested and 
ROS-related therapeutic mechanisms are illustrated.
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The dual capabilities of CONPs to act as an 
antioxidant in normal cells, yet oxidant in can-
cer cells, supports the role of CONPs as an 
adjuvant for RT that could significantly impact 
patient quality of life.
In line with the protection from other methods 
of inducing oxidative stress, several publica-
tions have shown that treatment with CONPs 
prior to RT exposure decreases the RT-induced 
cell damage and death in normal tissues of the 
gastrointestinal tract [19], lung [20], breast 
[21], and head and neck [22]. Mechanistically, 
CONP radical scavenging inhibited the resulting 
caspase 3 activation in irradiated colonic crypt 
tissue [19], as well as capsase 3 and 7 activa-
tion in irradiated lung fibroblasts in culture [20]. 
CONPs also increased super oxide dismutase 2 
(SOD2) expression up to two-fold in a dose 
dependent manner in normal human colon 
cells in vitro, while increasing SOD2 expression 
by 40% in colonic crypt cells from mice treated 
with CONPs [19]. Together, these data indicate 
that CONPs protect normal cells both directly, 
by scavenging cellular ROS, and indirectly, by 
priming cells to respond to ROS insult.
Conversely, in cancer cells with acidic pH, pre-
treatment with CONPs has been shown to 
enhance the ability of RT to induce cell death. 
As predicted [7], a most recent publication 
demonstrated the ability of CONPs to drive 
RT-induced ROS levels in pancreatic cancer 
cells [8]. As acidic pH has been shown to inhibit 
the catalase activity of CONPs [15], it is sug-
gested that CONPs in cancer cells are only 
capable of catalyzing the conversion of highly 
unstable superoxide to far more stable H2O2. 
Without the ability to act as a catalase mimetic 
and remove H2O2, CONPs actually enhance the 
toxicity of RT in cancer cells by encouraging the 
accumulation and stability of ROS in the cell 
[8]. These effects resulted in the radio-sensiti-
zation of pancreatic cancer, significantly 
decreasing cell viability in vitro [8]. In a pancre-
atic tumor bearing mouse model that received 
the combination therapy of CONPs prior to RT, 
significant decreases in tumor weight and vol-
ume correlated with an increase in the number 
of apoptotic cells in the tumors [8]. Overall, 
these data demonstrate that CONPs modulate 
ROS in cancer cells such that, not only are there 
direct toxic effects, but the therapeutic proper-
ties of CONPs extend to radio-sensitization of 
cancer cells and potentially sensitization to 
other ROS-inducing therapies.
CONP effect on other diseases
Beyond cancer, several other diseases are 
characterized by ROS accumulation. The inci-
dence and progression of neurodegenerative 
diseases is often linked with the buildup of 
ROS, which becomes detrimental as it over-
whelms cellular mechanisms to combat oxida-
tive stress [13]. Increased ROS provides the 
primary link between the cause of the disease 
and the associated neurodegeneration in 
Huntington Disease, Parkinson Disease, 
Alzheimer Disease, and age related macular 
degeneration (AMD) [13]. While researchers 
have yet to truly explore the potential therapeu-
tic benefits of CONPs in many of these diseas-
es, CONPs have been shown to scavenge ROS 
in mouse models of hereditary retinal degener-
ation, preventing deterioration of retinal func-
tion, as well as apoptosis in photoreceptor cells 
[12]. In a specific AMD model, CONPs scav-
enged ROS to prevent the associated increase 
in vascular endothelial growth factor (VEGF) 
expression in photoreceptor cells, thereby pre-
venting intra-retinal and sub-retinal neovascu-
lar lesions which lead to blindness [13]. 
Excitingly, CONP treatment was also able to 
induce the regression of pre-existing pathologic 
retinal neovasculature suggesting the anti-
angiogenic function of CONPs [13], and has 
been suggested to be applicable for the treat-
ment of other ocular disorders, such as diabet-
ic retinopathy [12, 13].
In the context of diabetes, increased ROS, 
especially in the liver which is responsible for 
removing free radicals, is established to be an 
important factor in the development and pro-
gression of the disease [14]. CONP treatment 
of diabetic rats was able to return hepatic ROS 
levels to levels comparable to those in non-dia-
betic rats, as well as decrease plasma triglycer-
ides and increase plasma HDL [14]. As many 
patients with insulin dependent diabetes 
require pancreatic islet transplantation, CONPs 
have also been tested for their ability to improve 
pancreatic islet function during isolation and 
transplantation procedures, during which oxi-
dative stress is an issue [23]. Pre-treatment 
with CONPs was shown to significantly increase 
viability and insulin secretion, while decreasing 
ROS levels in isolated, cultured pancreatic islet 
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cells [23]. Overall, CONPs show promise for 
addressing the various radical associated prob-
lems driving and resulting from diabetes.
Cellular uptake and localization of CONPs
CONPs have been shown to enter mammalian 
cells in both normal and diseased states [15, 
24, 25], with significant uptake occurring within 
3 hours of exposure in culture [26]. CONPs 
appear to take multiple routes into cells, as 
uptake has been suggested to occur via recep-
tor-mediated endocytosis in both lung cancer 
and normal lung cell lines [27], while other 
studies have shown CONP uptake via clathrin-
mediated and calveolae-mediated endocytitic 
pathways [26]. There is some debate about the 
fate of CONPs once inside the cell. Some stud-
ies show that CONPs accumulate in the cyto-
plasm without translocation to the nucleus [15, 
24]. Other studies have demonstrated that 
CONPs accumulate primarily in the peri-nuclear 
space [28], while still others detected CONPs 
co-localized with the mitochondria, endoplas-
mic reticulum, lysosomes, as well as diffused 
throughout the cytoplasm and nucleus [26]. 
Particle size and surface charge appear to be 
determinants of CONP uptake and cellular 
localization [7]. As the differential pH of various 
sub-cellular localizations has been shown to be 
a determinant of CONPs’ anti- or pro-oxidant 
activity [7], manipulation of CONPs to target 
specific cells or sub-cellular locations is a path 
that has yet to be fully elucidated and exploited 
(Figure 2).
Biodistribution and biopersistence of CONPs
Several reports have shown CONPs (<10 nm) to 
be well tolerated by animals without inducting 
overt toxicity or an immune response across a 
range of doses [19, 20, 29]. When adminis-
tered intravenously (i.v.) or intraperitoneally 
(i.p.), studies show that CONPs accumulate pri-
marily in the spleen and liver, to a lesser extent 
in the lungs and kidneys, but not in the heart or 
brain [29, 30]. Tissues such as the breasts and 
pancreas have not been analyzed for retention, 
yet nearly half of the injected CONPs remained 
in undetermined locations within the body [30]. 
Further, CONPs were not readily cleared, per-
sisting in the animals for at least 30 days with-
out any appreciable CONP concentration in the 
urine or feces [29, 30], suggesting that other 
CONP destinations within the body have yet to 
be identified.
CONP toxicity
Despite the apparent lack of toxicity in animal 
models, reports provide conflicting data about 
the toxicity of CONPs in vitro, likely attributable 
to the impact of undetermined cellular and 
environmental factors on the manifestation of 
anti- or pro- oxidant behavior. CONPs are toxic 
to bronchial epithelial lung fibroblasts in culture 
[28], but non-toxic to mammary epithelial cells 
Figure 2. pH-dependent activity of CONPs as pro- or anti-oxidants. In a neutral pH environment, CONPs act as anti-
oxidants that are cytoprotective. On the contrary, in an acidic pH environment, for example in cancer cells, CONPs 
function as pro-oxidants that are cytotoxic. Yet other factors likely exist that contribute to the switch between the 
pro-and anti-oxidant functions of CONPs.
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[21], macrophages [31], immortalized keratino-
cytes [26], or immortalized pancreatic epitheli-
al cells [8]. In normal cells to which they are not 
toxic, the physiological pH is an environment 
which enables canonical radical scavenging by 
CONPs. Therefore, CONPs introduced prior to 
ROS insult confer protection from the effects of 
oxidative stress in vitro and in vivo [13, 32-34].
However, published data indicates that CONPs 
are toxic to several types of human cancer cells 
in vitro, including squamous cell carcinoma 
[15], alveolar epithelial cancer cells [35], and 
pancreatic carcinomas [8]. Additionally, CONPs 
also display toxicity to pancreatic tumors in 
vivo, reducing tumor volume by almost 40% [8]. 
Cellular toxicity is attributed to the generation 
of ROS [8, 15] and the induction of oxidative 
stress [35], at least in part by the inherent oxi-
dase activity of the nanoparticle core at acidic 
pH similar to that of cancer cells [6]. In particu-
lar, CONP treatment has been shown to induce 
glutathione oxidation, lipid peroxidation, and 
membrane damage in lung cancer cells [35]. 
Further experiments have demonstrated that 
generation of CONPs with a negative surface 
charge can induce preferential accumulation in 
acidic lysosomes within the cell, resulting in 
increased toxicity selectively in cancer cells [7].
Conclusions
Despite conflicting in vitro data regarding toxic-
ity, in vivo data about the toxicity and applica-
tion of CONPs for the treatment of numerous 
diseases remains overwhelmingly positive thus 
far. In contrast with currently available ROS 
modulators, which are characterized by a short 
half-life and usually require the introduction of 
one antioxidant molecule for each radical to be 
scavenged, CONPs persist in the body with a 
single particle scavenging many free radicals or 
inducing the oxidation of several targets 
through its auto-regenerative capacity [12]. 
With ROS and oxidative stress linked to so 
many conditions, the number of potential appli-
cations for CONP-based therapies appears 
countless. While current research into the ther-
apeutic applications of CONPs leaves some 
questions unanswered, it provides a firm basis 
and evidence of a bright future for the pharma-
ceutical application of CONPs in cancer, diabe-
tes, and other ROS-linked disorders that have 
yet to be pursued.
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